Search research articles
Contact Us
Filters
Showing results (61-70 of 69) with videos related to
Page
of 7
Sort By:
You have reached the last page of results.
This site can display upto 69 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 1, 1996
Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer
P Bassa, E E Kim, T Inoue, et al.
Cancer
|
February 1, 1994
Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients
J L Murray, M G Rosenblum, H Z Zhang, et al.
Nuclear Medicine Communications
|
July 1, 1996
99Tcm-IMMU4 imaging in recurrent colorectal cancer: efficacy and impact on surgical management
R Sirisriro, D A Podoloff, Y Z Patt, et al.
Journal of Drug Targeting
|
January 1, 1996
Development of new markers for hypoxic cells: [131I]Iodomisonidazole and [131I]Iodoerythronitroimidazole
A Cherif, S Wallace, D J Yang, et al.
Journal of Pharmaceutical Sciences
|
March 1, 1996
Assessment of tumor cell proliferation using [18F]fluorodeoxyadenosine and[18F]fluoroethyluracil
C G Kim, D J Yang, E E Kim, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc
|
March 11, 1992
Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET
E E Kim, S K Chung, T P Haynie, et al.
Lancet (London, England)
|
February 24, 2001
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial
S M Tu, R E Millikan, B Mengistu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 1998
Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial
D J Macey, E J Grant, L Kasi, et al.
Critical Reviews in Oncology/Hematology
|
June 22, 2001
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
G A Wiseman, C A White, R B Sparks, et al.
Page
of 7
Search research articles
Search
Showing results (61-70 of 69) with videos related to
Sort By:
Page
of 7
You have reached the last page of results.
This site can display upto 69 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
June 1, 1996
Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer
P Bassa, E E Kim, T Inoue, et al.
Cancer
|
February 1, 1994
Comparative tumor localization of whole immunoglobulin G anticarcinoembryonic antigen monoclonal antibodies IMMU-4 and IMMU-4 F(ab')2 in colorectal cancer patients
J L Murray, M G Rosenblum, H Z Zhang, et al.
Nuclear Medicine Communications
|
July 1, 1996
99Tcm-IMMU4 imaging in recurrent colorectal cancer: efficacy and impact on surgical management
R Sirisriro, D A Podoloff, Y Z Patt, et al.
Journal of Drug Targeting
|
January 1, 1996
Development of new markers for hypoxic cells: [131I]Iodomisonidazole and [131I]Iodoerythronitroimidazole
A Cherif, S Wallace, D J Yang, et al.
Journal of Pharmaceutical Sciences
|
March 1, 1996
Assessment of tumor cell proliferation using [18F]fluorodeoxyadenosine and[18F]fluoroethyluracil
C G Kim, D J Yang, E E Kim, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc
|
March 11, 1992
Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET
E E Kim, S K Chung, T P Haynie, et al.
Lancet (London, England)
|
February 24, 2001
Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial
S M Tu, R E Millikan, B Mengistu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 17, 1998
Effect of recombinant alpha-interferon on pharmacokinetics, biodistribution, toxicity, and efficacy of 131I-labeled monoclonal antibody CC49 in breast cancer: a phase II trial
D J Macey, E J Grant, L Kasi, et al.
Critical Reviews in Oncology/Hematology
|
June 22, 2001
Biodistribution and dosimetry results from a phase III prospectively randomized controlled trial of Zevalin radioimmunotherapy for low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma
G A Wiseman, C A White, R B Sparks, et al.
Page
of 7